Clarity Pharmaceuticals Ltd.ASX: CU6

First FDA Breakthrough Therapy designation in PSMA PET

· Issued by Clarity Pharmaceuticals Ltd. via ASX

Filed with ASX · · 7 pages · English

Summary by 6ix AI

This designation is intended to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions. The designation was supported by data from clinical trials indicating enhanced diagnostic performance compared to standard care imaging. Clarity is currently conducting two Phase III trials for this product, with topline data expected in the near future.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

A S X A N N O U N C E M E N T 12 November 2026 First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company...

Clarity Pharmaceuticals Ltd. on 6ix

Story so far

Earlier from Clarity Pharmaceuticals

Later from Clarity Pharmaceuticals

All Clarity Pharmaceuticals news releases